^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | zotatifin (eFT226) (eIF4A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3399: Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
Published date:
04/27/2020
Excerpt:
Solid tumor xenograft models harboring FGFR1,2 or HER2 amplifications treated with eFT226 resulted in significant in vivo tumor growth inhibition and regression at well tolerated doses in breast, non-small cell lung and colorectal cancer models.
DOI:
10.1158/1538-7445.AM2020-3399
Source:
Title:
B133 - eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers
Published date:
10/28/2019
Excerpt:
Solid tumor xenograft models harboring FGFR1/2 or HER2 amplifications treated with eFT226 resulted in significant in vivo tumor growth inhibition and regression at well tolerated doses in breast, non-small cell lung and colorectal cancer models.
